Obesity and Type 2 Diabetes

Metabolic Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
ibipinabantPhase 2/31 trial
Active Trials
NCT00541567Withdrawn600Est. Jun 2010
NodThera
NodTheraPA - Philadelphia
1 program
1
NT-0796Phase 21 trial
Active Trials
NCT07055516Active Not Recruiting162Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers Squibbibipinabant
NodTheraNT-0796

Clinical Trials (2)

Total enrollment: 762 patients across 2 trials

BMS-646256 in Obese and Overweight Type 2 Diabetics

Start: Mar 2008Est. completion: Jun 2010600 patients
Phase 2/3Withdrawn

Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

Start: May 2025Est. completion: Mar 2026162 patients
Phase 2Active Not Recruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space